Amarin, FDA To Discuss Settling Off-Label Promotion Dispute
Amarin Pharma Inc. and the U.S. Food and Drug Administration have agreed to discuss settlement options following the company's landmark win in a suit in which a New York federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article